A5025445787- Cancer, Lipids, and Metabolism
- Cancer Genomics and Diagnostics
- MicroRNA in disease regulation
- Cancer Mechanisms and Therapy
- Colorectal Cancer Screening and Detection
- Circular RNAs in diseases
- Lipoproteins and Cardiovascular Health
- Cancer-related molecular mechanisms research
- Protease and Inhibitor Mechanisms
- Cancer Cells and Metastasis
- Colorectal and Anal Carcinomas
- Genetic factors in colorectal cancer
- Advanced Control Systems Optimization
- Cancer, Hypoxia, and Metabolism
- Colorectal Cancer Treatments and Studies
- Epigenetics and DNA Methylation
- RNA modifications and cancer
- Cytokine Signaling Pathways and Interactions
- Aerospace Engineering and Control Systems
- Cancer-related gene regulation
- Ubiquitin and proteasome pathways
- Optimization and Variational Analysis
- RNA Research and Splicing
- Lymphoma Diagnosis and Treatment
- Spacecraft Dynamics and Control
The University of Texas MD Anderson Cancer Center
2015-2025
Kyoto University
2022-2024
Sun Yat-sen University
2011-2016
Biocontrol (Brazil)
2014
Ministry of Education of the People's Republic of China
2014
Oncogenic KRAS (KRAS*) contributes to many cancer hallmarks. In colorectal cancer, KRAS* suppresses antitumor immunity promote tumor invasion and metastasis. Here, we uncovered that transforms the phenotype of carcinoma-associated fibroblasts (CAF) into lipid-laden CAFs, promoting angiogenesis progression. Mechanistically, activates transcription factor CP2 (TFCP2) upregulates expression proadipogenic factors BMP4 WNT5B, triggering transformation CAFs lipid-rich CAFs. These in turn, produce...
Aberrant activation of β-catenin in the nucleus has been implicated a variety human cancers, but fate nuclear is unknown. Here we demonstrate that tripartite motif-containing protein 33 (TRIM33), acting as an E3 ubiquitin ligase, reduces abundance protein. TRIM33-mediated destabilized and GSK-3β or β-TrCP independent. TRIM33 interacts with ubiquitylates β-catenin. Moreover, kinase Cδ, which directly phosphorylates at Ser715, required for TRIM33–β-catenin interaction. The function suppressing...
Abstract Malignant glioma is an often fatal type of cancer. Aberrant activation STAT3 leads to tumorigenesis. STAT3-induced transcription protein-coding genes has been extensively studied; however, little known about STAT3-regulated miRNA gene in In this study, we found that abnormal or decreased expression promotes inhibits the miR-182-5p, respectively. Bioinformatics analyses determined tumor suppressor protocadherin-8 (PCDH8) a candidate target miR-182-5p. miR-182-5p negatively regulated...
Emerging evidence suggests that cryptic translation within long noncoding RNAs (lncRNAs) may produce novel proteins with important developmental/physiological functions. However, the role of this in complex diseases (e.g., cancer) remains elusive. Here, we applied an integrative strategy combining ribosome profiling and CRISPR/Cas9 screening large-scale analysis molecular/clinical data for breast cancer (BC) identified estrogen receptor α–positive (ER+) BC dependency on ORFs encoded by...
Abstract Background: While detection of circulating tumor DNA (ctDNA) weeks after surgery is linked to recurrence for other solid tumors, the optimal time point ctDNA assessment as a prognostic biomarker following chemoradiation anal cancer undefined. Methods: Patients with stages I-III treated between 12/2020-5/2024 were evaluated HPV status at baseline, end chemoradiation, and during surveillance using droplet digital PCR assay targeting E6 E7 oncogenes 13 oncogenic types. Median...
Camptothecin (CPT) is an effective chemotherapeutic agent for treatment of patients with cancer. The mechanisms underlying CPT-mediated responses in cancer cells are not fully understood. MicroRNA (miRNA) play important roles tumorigenesis and drug sensitivity. However, the interaction between camptothecin miRNA has been previously explored. In this study, we verified that miR-125b was down-regulated CPT-induced apoptosis ectopic expression partially restored cell viability inhibited induced...
Abstract Background MicroRNA-133b (miR-133b), which is a muscle-specific microRNA, has been reported to be downregulated in human colorectal carcinoma (CRC) when compared adjacent non-tumor tissue. However, its diagnostic value and role CRC have yet described. CXC chemokine receptor-4 (CXCR4), participates multiple cell processes such as invasion-related signaling pathways, was predicted potential target of miR-133b. The aim this study investigate the associations functions miR-133b CXCR4...
MicroRNA-125b (miR-125b), a small noncoding RNA molecule, has been found to be deregulated and functions as an oncogene in many cancers including hematopoietic malignancies. However, the mechanisms accounting for miR-125b dysregulation remain elucidated. The present study aims identify factors that might contribute up-regulation of human malignancies its downstream targets lineage-specific differentiation. We at first reported CDX2, homeobox transcription factor, binds promoter regions gene...
Aberrant activation of β-catenin signaling is a critical driver for tumorigenesis, but the mechanism underlying this not completely understood. In study, we demonstrate role in stabilization enhancer zeste homolog 2 (EZH2) and control EZH2-mediated gene repression oncogenesis. β-Catenin/TCF4 activated transcription deubiquitinase USP1, which then interacted with deubiquitinated EZH2 directly. USP1-mediated promoted its recruitment to promoters CDKN1B, RUNX3, HOXA5, resulting enhanced...
Acute promyelocytic leukemia (APL) is characterized by the t(15;17)-associated PML-RARA fusion gene. We have previously found that MIR125B1 highly expressed in patients with APL and may be associated disease pathogenesis; however, mechanism which exerts its oncogenic potential has not been fully elucidated. Here, we demonstrated abundance correlates status. overexpression enhanced expression inhibited ATRA-induced degradation of oncoprotein. RNA-seq analysis revealed a direct link between...
3513 Background: Prior HPV infection is associated with > 90% of anal cancers, a malignancy rising incidence in the United States. Standard treatment for localized cancer concurrent chemoradiation (cRT). While detection circulating tumor DNA (ctDNA) within weeks after surgery linked to recurrence other solid tumors, optimal time point ctDNA as prognostic biomarker following cRT HPV-associated anogenital cancers not well characterized. We utilized novel, highly sensitive assay evaluate...
Background: To extend the practicality of liquid biopsy beyond historical HPV circulating tumor DNA (ctDNA) assays, we evaluated clinical relevance a novel next-generation sequencing ctDNA assay in patients with locally advanced and metastatic squamous cell cancer anal canal (mSCCA). Methods: isolated from plasma mSCCA was sequenced using 1.4 Mb hybrid-capture target-enrichment panel covering whole genome sequences all 193 types. The type, copy number (CN), integration sites were determined...
Abstract MAPK pathway inhibitors (MAPKi) are increasingly used in the treatment of advanced colorectal cancer, but often produce short-lived responses patients. Although acquired resistance by de novo mutations tumors have been found to reduce response some patients, additional mechanisms underlying limited durability targeting therapy remain unknown. Here, we denote new contributory tumor biology and provide insight on impact plasticity response. Analysis MAPKi treated patients revealed...
9 Background: While most patients with localized AC are cured by chemoradiation (cRT), some recur and require salvage surgery (SS). No adjuvant therapies effective after SS. We profiled cRT-refractory tumors from SS to identify biomarkers linked recurrence. Methods: Using an IRB-approved protocol, localized, were classified as recurrent (R; N=19) or non-recurrent (NR; N=10) according outcome Digital spatial profiling whole transcriptome analysis (GeoMx) on FFPE evaluated expression of 18000+...
Abstract Purpose: EGFR-targeting monoclonal antibodies are essential for managing RAS WT metastatic colorectal cancer (mCRC), but their limited efficacy necessitates exploring immunological and metabolic factors influencing response. This study evaluated glutamine metabolism targeting with EGFR inhibition to identify response biomarkers in patients prior anti-EGFR treatment progression. Experimental Design: We conducted a phase I/II trial KRAS mCRC patients, combining panitumumab CB-839,...
Abstract Background: Anti-PD-(L)1 antibodies are associated with responses in <25% of patients metastatic human papillomavirus (HPV)-associated malignancies. VEGF signaling causes intratumoral immune evasion and suppression. We evaluated the anti-PD-L1 antibody atezolizumab anti-VEGF bevacizumab for unresectable, advanced anal cancer. Patients methods: For this phase II study, participants previously treated, immunotherapy-naïve cancer received (1200 mg) (15 mg/kg) intravenously every...
Background/Objectives: Anal cancer is a rare malignancy with limited treatment options. Immune checkpoint inhibitors have shown benefits in some patients metastatic disease, but predictive factors for immunotherapy response remain undefined. This study retrospectively evaluated clinical and pathological features associated survival outcomes anal treated immunotherapy. Methods: Data from 105 were analyzed. Kaplan–Meier analysis was used to estimate progression-free (PFS) overall (OS),...
Emerging evidence suggests that cryptic translation beyond the annotated translatome produces proteins with developmental or physiological functions. However, functions of non-canonical open reading frames (ORFs) in cancer remain largely unknown. To fill this gap and systematically identify colorectal (CRC) dependency on ORFs, we apply an integrative multiomic strategy, combining ribosome profiling a CRISPR-Cas9 knockout screen large-scale analysis molecular clinical data. Many such ORFs are...
The implications of intratumor heterogeneity on the four consensus molecular subtypes (CMS) colorectal cancer (CRC) are not well known. Here, we use single-cell RNA sequencing (scRNASeq) to build an algorithm assign CMS classification individual cells, which explore distributions CMSs in tumor and non-tumor cells. A dataset tumors with bulk RNAseq (
Acute lymphoblastic leukemia (ALL) is an aggressive malignant disorder of lymphoid progenitor cells in both children and adults. Although improvements contemporary therapy development new treatment strategies have led to dramatic increases the cure rate with ALL, relapse remains high prognosis relapsed childhood ALL poor. Molecularly targeted therapies emerged as leading treatments cancer therapy. Multi-cytotoxic drug regimens achieved success, yet many studies addressing focused on only one...
PURPOSE Activating mutations in KRAS, NRAS, and BRAF are known to cause resistance anti–epidermal growth factor receptor (EGFR) therapy; however, only approximately 40% of patients with colorectal cancer (CRC) RAS WT tumors respond anti-EGFR treatment. We sought discover novel biomarkers predict response antibody treatment CRC understand mechanisms therapy. MATERIALS AND METHODS Transcriptomic profiles from three clinical two preclinical cohorts treated cetuximab were used assign consensus...